We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSALV
RNS Number : 3501D
SalvaRx Group plc
09 October 2018
SalvaRx Group plc
("SalvaRx" or the "Company")
Exercise of Warrants
SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that the Company has issued and allotted 60,563 ordinary shares of 2.5 pence each in the capital of the Company ("Ordinary Shares") at a price of 35.5 pence per share following an exercise of warrants.
The Company has made an application for the 60,563 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur at 8.00 a.m. on 12 October 2018. The 60,563 new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Total Voting Rights
For the purpose of the Disclosure and Transparency Rules, following Admission, the Company's total issued ordinary share capital will consist of 36,527,182 Ordinary Shares. The Company does not hold any shares in treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.
Enquiries
SalvaRx Group plc Ian B. Walters, MD (Chief Executive) Tel: +1 203 441 5451 Northland Capital Partners Limited Tel: +44 (0) 20 3861 6625 Nominated Adviser and Broker Matthew Johnson / Edward Hutton (Corporate Finance) Vadim Alexandre (Corporate Broking)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
MSCZMMGGGRGGRZZ
(END) Dow Jones Newswires
October 09, 2018 02:00 ET (06:00 GMT)
1 Year Salvarx Chart |
1 Month Salvarx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
